Melanoma is among the most aggressive and common cancers. Surgery, chemotherapy, and radiation therapy have been the mainstay of melanoma treatment, but they fail to control aggressive tumors, especially when resistance develops.
Health Professionals
Drug Combination Proves More Effective for Patients with Advanced Stage 3 Melanoma
Patients with advanced stage 3 melanoma that has spread to the regional lymph nodes but not yet to distant organs appear to benefit from a novel combination of two drugs rather than just one as currently applied in standard practice, researchers found.
Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression
Gino Kim In, MD, a medical oncologist, Medical Oncology, Melanoma Surgery, Sarcoma and Melanoma Surgery and associate professor of clinical medicine at Keck School of Medicine of the University of Southern California, discussed the safety and efficacy of superficial and deep or visceral vusolimogene oderparepvec (RP1) injection in a registrational cohort of patients from the phase 3 IGNYTE trial (NCT03767348) with melanoma who progressed on anti–PD-1 inhibitors.
Reduction in length of immunotherapy treatment for hard-to-treat melanoma shows promise in clinical trial
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to new research led by the Universities of Sheffield.